

Animal Models: Value and Translational Potency

Philipp Mergenthaler and Andreas Meisel

WHAT IS THE VALUE OF ANIMAL MODELS? PATHOPHYSIOLOGICAL CONCEPTS

The majority of translational research relies on preclinical animal models. However, given an incredible number of examples of failed translation, that is, phase II or phase III clinical trials, which were not able to reproduce the beneficial effect of preclinical findings (O'Collins et al., 2006; Perrin, 2014; Prinz, Schlange, and Asadullah, 2011), the translational value of animal models has been questioned. In particular, rodent models have been accused of falsely modeling human disease conditions.

Nonetheless, many animal models are geared to replicate pathophysiological conditions found in patients. An ideal animal model of a human disease is characterized by similarities between both in terms of (1) pathophysiology, (2) phenotypic and histopathological characteristics, (3) predictive biomarkers for course or prognosis, (4) response to therapies, and (5) drug safety or toxicity (Perrin, 2014; Prabhakar, 2012).

Four types of animal models are used in preclinical research: (1) disease induction models, (2) xenograft animal models, (3) inbred strains, and (4) transgenic models (Prabhakar, 2012). The rodent stroke model of middle cerebral artery occlusion is a typical disease induction model. Xenografting, or transplantation of organs or tissues from one species into another, is often used in cancer research. "Humanized" mice are another example of xenograft models (see later). Inbred animals are genetically homogeneous, allowing investigation of pathobiology with small sample sizes (Prabhakar, 2012). Through the use of molecular biology methods, specific genes are either deleted (knock-out), mutated, or overexpressed in transgenic animals, mainly mice. Often these models are combined; e.g., disease induction models in transgenic mice are often used to investigate the contribution of specific genes in diseases.

Rodent models of cerebral ischemia are good examples of animal models that replicate human pathophysiology well (Astrup et al., 1977; Heiss, 2011). The ischemic penumbra is defined as the area surrounding the core of the ischemic lesion. While physiological cascades are compromised, this area of brain tissue can potentially be rescued by medical intervention. This concept was first described in animal models (Astrup et al., 1977; Heiss, 2011) and has since been found to be relevant for human stroke pathophysiology (Dirnagl, Iadecola, and Moskowitz, 1999; Donnan et al., 2008; Mergenthaler, Dirnagl, and Meisel, 2004; Mergenthaler and Meisel, 2012). The same has been found true for the concept of stroke-induced immunodepression. While the pathophysiological concept has initially been described in animal models (Chamorro et al., 2012; Prass et al., 2003), clinical trials have been able to replicate this concept in human stroke pathophysiology (Chamorro et al., 2012; Harms et al., 2008; Mergenthaler and Meisel, 2012), albeit therapeutic protocols making use of this concept are still under development (Mergenthaler and Meisel, 2012).

Likewise, animal models of cancer, and in particular genetically engineered mouse models, have significantly contributed to the understanding of tumor biology and cancer pathophysiology. In particular, advances in genetic engineering have allowed modeling the manifold genetic defects underlying many forms of cancer (Cheon and Orsulic, 2011). Likewise, the concept that several mutations in the genome might be required for tumor development as well as prototypic oncogenes has been established by the use of mouse models (Cheon and Orsulic, 2011). However, similar to the situation in stroke (Dirnagl and Fisher, 2012), mouse models in preclinical cancer research have yet to prove their translational capacity (Cheon and Orsulic, 2011).

WHAT IS A GOOD ANIMAL MODEL FOR TRANSLATIONAL RESEARCH?

It is clear that there is no single ideal animal model of human disease conditions. Likewise, the design of preclinical experimental studies at present offers substantial room for improvement. While this topic has recently received significant

attention, many of the proposed remedies for the “translational roadblock” have yet to prove themselves in translational studies and the design of clinical trials. Among others, considering the complex characteristics of the animal models as well as of the human disease state is essential when selecting an appropriate model for preclinical studies. Three aspects are often not considered in preclinical studies: the heterogeneous nature of disease, the presence of comorbidities, and appropriate outcome measures (Mergenthaler and Meisel, 2012).

Several approaches to improve translation from animals to the clinic have been suggested. Before clinical trials are started, preclinical investigations should be performed in multiple experimental settings involving different small and large animals modeling different disease states, including the characterization of the optimal therapeutic window, optimal administration routes and schemes, as well as dose–response curves (Xiong, Mahmood, and Chopp, 2013). Furthermore, preclinical studies need to reflect the clinical scenarios. Importantly, these include relevant treatment windows and outcome parameters. For example, drug administration at onset or even before injury, as performed in many preclinical studies investigating disease mechanisms, is of minor relevance for therapy.

Most preclinical research in stroke or traumatic brain injury (TBI) suffers from short-term studies demonstrating treatment effects 1 – 7 days after the event (Xiong, Mahmood, and Chopp, 2013). Investigations on long-term outcome weeks to months after injury are still scarce. On the contrary, primary endpoints of clinical phase III trials have to focus on relevant long-term outcome measures.

Disease modeling focused on pathophysiological research is invariably an oversimplification of the clinical situation. For example, stroke patients often suffer from a variety of other diseases such as hypertension, diabetes mellitus, or chronic obstructive pulmonary disease, **which are commonly not modeled.** Beyond the comorbidities patients have before stroke onset, patients are often affected by several post-stroke complications, such as infection or depression, which are also usually either not modeled or not considered. The same holds true for other disease models such as TBI. Moreover, stroke patients receive a myriad of treatments including medication and general care such as nursing and physiotherapy, among others. Although stroke unit care is efficient without any doubt, we do not know which single pieces of treatment are of relevance. Nevertheless, modeling of care is probably one prerequisite in successful translation of treatment strategies of complex disorders such as stroke (Mergenthaler and Meisel, 2012).

Modeling Comorbidities

Most investigators disregard the fact that most patients are not young or middle-aged males without any comorbidities (Howells et al., 2010; Sena et al., 2010). One fundamental criticism of animal research is that most models do not consider age (Howells et al., 2010), which is one of the most relevant cofactors of outcome for most noncommunicable disorders (Howells et al., 2010; Lozano et al., 2012). However, young to middle-aged inbred rodents of one gender and of homogeneous genetic backgrounds are typically used for preclinical animal studies. Ideally, preclinical animal studies should use animal populations of mixed gender, advanced age, and with various comorbidities, such as diabetes mellitus, hyperlipidemia, hypertension, obesity, or other risk factors that are relevant for the respective human disease. Such an approach would model the human etiology of most diseases more closely. In many cases, such models are readily available (Howells et al., 2010). In addition, experimental animal populations should be increasingly complex as a therapeutic intervention advances in the translational pipeline (Figure 2.14). The concept of establishing a framework as well as funding schemes to enable such preclinical randomized controlled trials (pRCTs) has been suggested in many medical disciplines including cancer (Cheon and Orsulic, 2011) and stroke (Bath, Macleod, and Green, 2009; Dirnagl and Fisher, 2012; Mergenthaler and Meisel, 2012).

Modeling Care of Patients

Many successful therapeutic strategies rely on “intensified care” of (critically ill) patients in the acute phase of the disease on dedicated and highly specialized hospital wards. Acute care is usually complex and committed to optimize physiological parameters. Including such a strategy in preclinical modeling would aid in better modeling clinical care of patients as well as its associated complications.

In cerebral ischemia, stroke units are prepared to treat the clinical condition as well as potential complications (Donnan et al., 2008). Infections have largely been neglected in preclinical stroke research (Meisel and Meisel, 2011; Meisel et al., 2005), although they heavily influence stroke outcome (Mergenthaler and Meisel, 2012; Westendorp et al., 2011). Preventive antibacterial treatment not only prevents infections but also improves survival and neurological outcome after experimental stroke compared with placebo treatment (Meisel et al., 2004); recent phase IIb trials have successfully proven this experimental concept (Chamorro et al., 2005; Harms et al., 2008; Schwarz et al., 2008) by demonstrating that prevention of infection is effective in stroke patients (van de Beek et al., 2009). Thus, basic research findings and preclinical modeling preceded the development of this new treatment approach (Mergenthaler and Meisel, 2012).




FIGURE 2.14 The preclinical trial phases of translational research. As therapeutic agents or concepts advance in development, the experimental setting increases in complexity. It ranges from small cohorts to investigate novel mechanisms to large mixed populations with (multiple) comorbidities and additional modeling of stroke care. The final stage of preclinical development is the conduct of a randomized-controlled preclinical trial (RCPT), ideally in a stroke unit setting. Randomized clinical trials (RCT) commence after this process has been completed and is based on evidence gained in preclinical testing. (Reproduced with permission from Mergenthaler P and Meisel A. (2012). *Do stroke models model stroke?* Dis. Model Mech. 5, 718–725.)

A novel approach to preclinical research would include modeling the acute, subacute, and chronic phase of disease. Clinical and empirical evidence indicate that intensified and specialized treatments are beneficial for long-term outcome. Thus, taking “care” of patients should be reflected in future preclinical trials. In summary, preclinical trials as the foundation for future clinical trials should include large and complex cohorts of animals, and include gender-mixed, aged animals from different strains, ideally with different comorbidities, and model care of (hospitalized) patients. Furthermore, complex long-term outcome analyses should be performed to evaluate the success of a novel therapeutic concept or pharmacological agent (Figure 2.14).

WHAT IS THE TRANSLATIONAL VALUE OF ANIMAL MODELS?

Recurrent failure to translate promising treatment strategies in animal models into the clinic has challenged the value of animal research for predicting the effectiveness of treatment strategies in humans. Thus, animal models of human disorders are more and more condemned, have been considered meaningless or at best as imprecise for the human setting, and all medical areas employ models that have advantages or limitations. At least, animal models are used successfully to define basic pharmacokinetic properties as well as to investigate safety and toxicity issues (McGonigle and Ruggeri, 2014).

One example for this approach is the following. The devastating neurodegenerative disorder amyotrophic lateral sclerosis (ALS) is characterized by a progressive degeneration of motor neurons leading to a generalized paralysis, respiratory insufficiency, and death usually within 3 – 5 years. Stem cell transplantation has emerged as a promising approach for ALS patients. Rather than motor neuron replacement, current approaches consider mesenchymal or neural stem cells as supporters for motor neurons, delaying neurodegeneration. Although some ALS models suggest that stem-cell-based approaches might delay motor neuron degeneration, current strategy in the field is rather not proving efficacy than demonstrating safety in preclinical models aiming at quick “translation” to the clinical setting investigating efficacy in patients. The main argument for this approach is the rather poor understanding of the ALS pathobiology (Thomsen et al., 2014). However, whether or not this safety-focused approach in translation is successful remains to be demonstrated.

Even preclinical studies aiming at toxicity analysis might fail in predicting safety for humans. For example, the immunomodulatory humanized agonistic anti-CD28 monoclonal antibody TGN1412, which was developed for autoimmune disorders such as multiple sclerosis or rheumatoid arthritis, was tested successfully for safety in various animal models including mice. However, in the first in man (phase I) trial, TGN1412 caused a severe systemic inflammatory response syndrome due to a “cytokine storm,” resulting in a disastrous outcome with a multi-organ failure for the study participants, despite the fact that the dose used was 500 times lower than the dose found to be safe in animal studies (Suntharalingam et al., 2006).

Drug discovery begins with target identification and validation and proceeds with identification and development of candidate therapeutic agents. At each step of this process, which often requires more than 12 years, animal models are needed (Whiteside, Pomonis, and Kennedy, 2013). However, only 15% of novel drugs successfully tested in animal models pass early clinical trials, and approximately half of them surviving phase III become finally approved by the regulatory authorities for clinical practice (Ledford, 2011).

Extrapolation of preclinical findings into the clinical settings might also depend on the substances under investigation. For example, animal models mimicking airway susceptibility in different lung disorders have been demonstrated to be predictive for the human situation for anesthetic drugs like halothane, isoflurane, propofol, and ketamine, but not lidocaine, morphine, or muscle relaxants. Among others, variability between species in different receptor distributions and drug affinities might account for the different predictability of the preclinical models (Habre and Petak, 2013).

Animal models of human tumors are considered as indispensable for drug discovery and development. The commonly used ectopic and orthotopic xenografts models, primary human tumorgraft models, genetically engineered models, or various multistage carcinogen-induced models all have different strengths and weaknesses (Cheon and Orsulic, 2011; Heyer et al., 2010). These models should be used as sophisticated biological tools at specific stages of drug development in a hierarchical manner of increasingly complex modeling (Figure 2.14) of the diversity of human cancers (Ruggeri, Camp, and Miknyoczki, 2014).

One approach to test the predictive power of animal models is to conduct reverse-translational studies investigating known effective treatment strategies of human disorders in appropriate animal models. Temozolomide is a good example of a successful forward and reverse translational approach for the treatment of glioblastoma. A systematic review and meta-analysis of temozolomide in animal models of glioblastoma predicted clinical efficacy. This treatment is effective in reducing tumor volume and improving survival clinically as well as in experimental models of malignant glioma. The reported efficacy for treatment has not significantly changed after publication (Hirst et al., 2013) of the seminal phase III temozolomide trial demonstrating efficacy in glioblastoma patients (Stupp et al., 2005), although evidence suggests a publication bias overemphasizing its therapeutic efficacy (Hirst et al., 2013).

Genetic mouse models of Huntington's disease (HD) should help to identify and prioritize the most promising treatment strategies to be tested in clinical trials (Menalled and Brunner, 2014). Many neural circuits affected by Huntington's disease are evolutionarily conserved. More than a dozen genetic mouse models express a mutation similar to that responsible in HD with many variations in CAG length of the Huntington gene. These models mimic the human genetic insult with different phenotypic aspects of HD (Menalled and Brunner, 2014).

Numerous transgenic or surgically induced pig models of neurodegenerative disorders have been established in order to develop cell-replacement strategies. Defining the optimal cell dose and immunosuppression protocols and testing new cell delivery devices were prerequisites for designing human clinical trial protocols in neurodegenerative disorders such as ALS, stroke, spinal cord and traumatic brain injury, Huntington's disease, Alzheimer's disease, and Parkinson's disease. In contrast to other animal models, fully or partially MHC-matched pig strains model the human situation, thereby better modeling host versus graft and graft versus host reactions of cell and tissue replacement strategies (Dolezalova et al., 2014).

In neuropathic pain research, the effect size of successful pain treatment is almost twice in animal models as in clinical trials. Correspondingly, the number needed to treat (NNT), which reflects the number of individuals that must be treated in order to see one successful treatment outcome, is almost half in animal compared to clinical pain trials. Among others, placebo effects in clinical trials, which are absent in animal research, are significant confounders. Effect sizes of at least 60% pain relief in animal models are required to predict clinical efficacy (Whiteside, Pomonis, and Kennedy, 2013).

Psychiatric disease is not directly translatable to animal models. For example, even transgenic mouse models of neuropsychiatric disorders cannot fully represent the broad spectrum of symptoms, including confusion or suicidal thoughts. However, these models serve to explore psychiatric disorders by unraveling disturbances of neural circuits underlying disease-relevant phenotypes, in particular how environmental and (epi-)genetic factors interact to shape behavioral phenotype and predispositions to psychiatric disorders (Donaldson and Hen, 2015). Traditionally, in psychiatric animal models, abnormal animal behavior was created, phenotypically resembling the aspects of mental disorders. Reverse translation using knowledge about the mechanisms of human disorders has been used to identify and develop animals that have the molecular and cellular abnormalities found in these diseases (Malkesman et al., 2009). For example, depression has been modeled in mice having point mutations in the mitochondrial DNA polymerase (Kasahara et al., 2006) and glutamate receptor 6 knockout mice have a high face and predictive validity for mania (Shaltiel et al., 2008).

"Lost in translation" has become a very popular paraphrase for the obstacles encountered in translational research. Three reasons for the "Lost in Translation Problem" have been suggested. First, small differences in the models might lead to vast differences in the results, which has been attributed to the chaotic behavior of the models and termed the "butterfly effect." Second, the effect size is decreasing from biochemical models over cell and tissue cultures to animal experiments to human studies, which seems to be unexpected according to the "princess and the pea" story. Finally, the "two cultures" of preclinical and clinical research are different (Ergorul and Levin, 2013; Mergenthaler and Meisel, 2012).

REMEDIES FOR FAILED TRANSLATION: IMPROVING PRECLINICAL RESEARCH

Improving Models

In order to improve the quality of translational biomedicine, it has been suggested to make the process of preclinical research more like clinical research. Among them, applying similar rules used by regulatory agencies for clinical trial has been suggested also for preclinical studies. **Using methods such as systematic reviews and meta-analyses has become more and more popular in animal research to identify robust treatment effects. Commonly accepted “futility” and “stopping” rules in clinical research become increasingly accepted in preclinical research.** These approaches have been demonstrated to improve the predictive value of animal research (Perel et al., 2007).

An ideal animal model will meet all the following three criteria: face validity, predictive validity, and construct validity. Face validity refers to the phenomenological similarity between the model and its corresponding disorder. Predictive validity refers to the ability of the model to have comparable biomarkers and treatment responses as the human disorder. Construct validity reflects the degree to which a model measures what it claims to be measuring (Willner, 1986).

In order to improve construct validity, it has been proposed that therapeutic interventions should be tested in animal models of central nervous system (CNS) disorders under conditions of greater environmental enrichment. One limitation of current research is that most animal studies are performed under caging conditions with sedentary, unstimulated animals having unlimited access to food. Enriched environments stimulating sensory system, cognition, and physical exercise have been demonstrated to affect outcome significantly (McOmish, Burrows, and Hannan, 2014).

In order to improve translational power, the use of more humanized models has been suggested (Ergorul and Levin, 2013). Immunodeficient mice that have been engrafted with human primary hematopoietic cells and tissues generating a functional human immune system in these mice are well-established examples of humanized mice. These models have been successfully used to investigate infectious diseases, autoimmune disorders, and tumors (Shultz et al., 2012).

Recent exciting findings in stem cell biology open the door to novel approaches in disease modeling. Terminally differentiated human somatic cells may be reprogrammed to a pluripotent stem cell (iPSC) state in order to then differentiate these cells into any cell type of interest (Lee and Studer, 2010). These developments might revolutionize investigations of human disorders, in particular those affecting the CNS (Philips, Rothstein, and Pouladi, 2014). Accessible cells from patients, e.g., fibroblasts from skin or monocytes from blood, might be used to generate iPSCs. These cells might be differentiated in specific neuronal subpopulations, e.g., striatal medium spiny neurons (Philips, Rothstein, and Pouladi, 2014), which are affected in brains of patients suffering from Huntington’s disease. Obviously, these cells are not directly accessible, neither for study disease mechanisms nor for specific treatment. Using iPSC technology and refined genomic editing tools correction of mutations is feasible, and specific treatment is conceivable (Kaye and Finkbeiner, 2013).

However, cell-based models cannot reflect the complexity of an organism. For example, investigating systemic effects of local disease, such as post-stroke pneumonia, requires animal models (Prass et al., 2003) to complement mechanistic cellular modeling. Another example is the blood–brain barrier (BBB), a highly selective permeability barrier separating the blood from the brain extracellular fluid. Although sophisticated in vitro models of BBB have been developed in the last decade, drug transport across the BBB and brain-specific drug delivery strategies remain challenging for development of successful treatment strategies (Bicker et al., 2014). Enzymes usually cannot pass the BBB. However, local enzyme replacement therapy in the brain by intrathecal application is a promising strategy for the treatment of patients with metabolic disorders caused by the absence or malfunction enzymes involved in cerebral metabolism. For example, repeated injections of a recombinant enzyme into the spinal fluid (intrathecal) corrects enzyme deficiency and normalizes lysosomal storage in a canine model of mucopolysaccharidosis (Dickson and Chen, 2011).

Improving Rigor of Preclinical Studies

The lack of reproducibility of preclinical studies and the failure of translation to the clinic have attracted attention in the last few years (Howells, Sena, and Macleod, 2014; Ioannidis, 2005; Macleod et al., 2014; Perrin, 2014; Prinz, Schlange, and Asadullah, 2011). One important reason is the publication bias toward reporting positive results due to difficulties or missing incentives in publishing negative results (Dirnagl and Lauritzen, 2010; Dwan et al., 2013). Moreover, experimental design, including statistics, has been challenged as a quality problem in preclinical trials. For example, definition and declaration of statistical approaches and endpoint measures need to be performed before preclinical trials are finally analyzed or even started (Dirnagl and Lauritzen, 2011). Whereas clinical trial registries are widely accepted as good clinical research practice, preclinical trial registries are rather uncommon and need to be established. Thereby, post-hoc analyses generating hypotheses in an exploratory manner can be clearly distinguished from a primary hypothesis that has been tested in a confirmatory approach. *A priori* power calculations and sample size considerations, randomized assignment to groups, and blinding for treatment groups are further important issues well established in clinical but not preclinical research.


Finally, it has been suggested that bringing the rigor and quality of study design expected in clinical trials to preclinical trials will improve translational success (Dirnagl and Fisher, 2012; Macleod et al., 2014). This includes **better knowledge about the drug before starting a preclinical trial**. For example, pharmacokinetics might be different between mutants and wild-type mice (Menalled et al., 2010). Confirmation of research findings includes replication of preclinical research in independent laboratories (Figure 2.15). Using different models will increase robustness of the observed findings in treatment effects (Menalled and Brunner, 2014).

Endpoint measures are of great importance in preclinical research as well as in clinical research and should therefore follow endpoints used in clinical research as close as possible. For example, Huntington's disease is characterized not only by motor symptoms but also by cognitive and psychiatric symptoms appearing years before the loss of motor control. These complaints often have a large impact on the quality of life. Although survival also is an important outcome measure in clinical trials, caution is required when translating preclinical into clinical findings. In contrast to animals even in preclinical research, survival in patients depends not only on the specific intervention under investigation but also on general care as well as ethical and religious issues leading to end-of-life decisions.

Specific suggestions for improving the predictiveness of preclinical stroke research have been oriented on accepted standards of clinical research (Bath, Macleod, and Green, 2009; Macleod et al., 2009; Mergenthaler and Meisel, 2012). In order to improve internal validity, good clinical research avoids any kind of bias, in particular selection bias (biased allocation to treatment groups), performance (biased care of treatment groups apart from intervention under study), assessment (biased rating due to knowledge of treatment assignment), and attrition (biased handling of protocol violation and loss in follow-up).

Preclinical research in the final stages of translation into clinical trials should follow the guidelines of clinical research by (1) improving internal validity by predefined inclusion/exclusion criteria and primary endpoint(s), randomization, blinding for treatment allocation, and outcome assessment intention-to-treat analysis; (2) improving external validity by studying pathophysiology and treatment strategies in animals of both sexes, old age, and with comorbidities, disease-related appropriate dosing, and treatment windows for the drug under investigation; (3) replicating pivotal findings; (4) publishing negative as well as positive results; (5) focusing on long-term functional outcome; and (6) using meta-analyses of preclinical studies; (7) establishing registries of preclinical studies; and (8) establishing international multicenter phase III preclinical trials (Dirnagl and Endres, 2014; van der Worp et al., 2010). Moreover, preclinical trials need a standardized and "humanized" modeling of general as well as disease-specific patient care (Mergenthaler and Meisel, 2012).

FIGURE 2.15 Modeled after randomized controlled clinical trials (RCTs), the final stage of preclinical testing is to conduct a randomized controlled preclinical trial (RCPT). A steering committee agrees on the intervention to be tested and all related aspects (e.g., models, outcome parameters, etc.). All administrative matters are centrally organized by a preclinical research organization (pCRO) and include objective criteria for the recruitment of study sites, the modes of randomization, collection of the data from the study sites, and central monitoring of all aspects of the trial. Ideally, all study sites are capable of performing the same experiments (i.e., they have access to the same models and equipment). All aspects of the RCPT are monitored by an independent organization. (Reproduced with permission from Mergenthaler P and Meisel A. (2012). *Do stroke models model stroke?* Dis Model Mech. 5, 718–725.)



SUMMARY

In summary, many well-defined animal models for human disease are employed in modern preclinical and pathophysiology-driven research. However, the scientific community across all fields of modern biomedicine has become aware of weaknesses in current preclinical animal modeling. Here, we have outlined several strategies that have already been set into action to overcome the translational gap that is common to all current preclinical modeling of human disease.

REFERENCES

- Astrup, J., Symon, L., Branston, N.M., Lassen, N.A., 1977. Cortical evoked potential and extracellular K^+ and H^+ at critical levels of brain ischemia. *Stroke* 8, 51–57.
- Bath, P.M., Macleod, M.R., Green, A.R., 2009. Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. *Int. J. Stroke* 4, 471–479.
- Bicker, J., Alves, G., Fortuna, A., Falcao, A., 2014. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. *Eur. J. Pharm. Biopharm.* 87, 409–432.
- Chamorro, A., Horcajada, J.P., Obach, V., Vargas, M., Revilla, M., Torres, F., et al., 2005. The early systemic prophylaxis of infection after stroke study: a randomized clinical trial. *Stroke* 36, 1495–1500.
- Chamorro, A., Meisel, A., Planas, A.M., Urra, X., van de Beek, D., Veltkamp, R., 2012. The immunology of acute stroke. *Nat. Rev. Neurol.* 8, 401–410.
- Cheon, D.J., Orsulic, S., 2011. Mouse models of cancer. *Annu. Rev. Pathol.* 6, 95–119.
- Dickson, P.I., Chen, A.H., 2011. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. *Curr. Pharm. Biotechnol.* 12, 946–955.
- Dirnagl, U., Endres, M., 2014. Found in translation: preclinical stroke research predicts human pathophysiology, clinical phenotypes, and therapeutic outcomes. *Stroke* 45, 1510–1518.
- Dirnagl, U., Fisher, M., 2012. International, multicenter randomized preclinical trials in translational stroke research: it's time to act. *J. Cereb. Blood Flow Metab.* 32, 933–935.
- Dirnagl, U., Iadecola, C., Moskowitz, M.A., 1999. Pathobiology of ischaemic stroke: an integrated view. *Trends Neurosci.* 22, 391–397.
- Dirnagl, U., Lauritzen, M., 2010. Fighting publication bias: introducing the negative results section. *J. Cereb. Blood Flow Metab.* 30, 1263–1264.
- Dirnagl, U., Lauritzen, M., 2011. Improving the quality of biomedical research: guidelines for reporting experiments involving animals. *J. Cereb. Blood Flow Metab.* 31, 989–990.
- Dolezalova, D., Hruska-Plochan, M., Bjarkam, C.R., Sorensen, J.C., Cunningham, M., Weingarten, D., et al., 2014. Pig models of neurodegenerative disorders: utilization in cell replacement-based preclinical safety and efficacy studies. *J. Comp. Neurol.* 522, 2784–2801.
- Donaldson, Z.R., Hen, R., 2015. From psychiatric disorders to animal models: a bidirectional and dimensional approach. *Biol. Psychiatry.* 77, 15–21.
- Donnan, G.A., Fisher, M., Macleod, M., Davis, S.M., 2008. Stroke. *Lancet* 371, 1612–1623.
- Dwan, K., Gamble, C., Williamson, P.R., Kirkham, J.J., Group, Reporting Bias, 2013. Systematic review of the empirical evidence of study publication bias and outcome reporting bias—an updated review. *PLoS One* 8, e66844.
- Ergorul, C., Levin, L.A., 2013. Solving the lost in translation problem: improving the effectiveness of translational research. *Curr. Opin. Pharmacol.* 13, 108–114.
- Habre, W., Petak, F., 2013. Anaesthesia management of patients with airway susceptibilities: what have we learnt from animal models? *Eur. J. Anaesthesiol.* 30, 519–528.
- Harms, H., Prass, K., Meisel, C., Klehmet, J., Rogge, W., Drenckhahn, C., et al., 2008. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. *PLoS One* 3, e2158.
- Heiss, W.D., 2011. The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke. The Johann Jacob Wepfer Award 2011. *Cerebrovasc. Dis.* 32, 307–320.
- Heyer, J., Kwong, L.N., Lowe, S.W., Chin, L., 2010. Non-germline genetically engineered mouse models for translational cancer research. *Nat. Rev. Cancer* 10, 470–480.
- Hirst, T.C., Vesterinen, H.M., Sena, E.S., Egan, K.J., Macleod, M.R., Whittle, I.R., 2013. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? *Br. J. Cancer* 108, 64–71.
- Howells, D.W., Porritt, M.J., Rewell, S.S., O'Collins, V., Sena, E.S., van der Worp, H.B., et al., 2010. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. *J. Cereb. Blood Flow Metab.* 30, 1412–1431.
- Howells, D.W., Sena, E.S., Macleod, M.R., 2014. Bringing rigour to translational medicine. *Nat. Rev. Neurol.* 10, 37–43.
- Ioannidis, J.P., 2005. Why most published research findings are false. *PLoS Med.* 2, e124.
- Kasahara, T., Kubota, M., Miyauchi, T., Noda, Y., Mouri, A., Nabeshima, T., et al., 2006. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. *Mol. Psychiatry* 11, 577–593, 523.
- Kaye, J.A., Finkbeiner, S., 2013. Modeling Huntington's disease with induced pluripotent stem cells. *Mol. Cell Neurosci.* 56, 50–64.
- Ledford, H., 2011. Translational research: 4 ways to fix the clinical trial. *Nature* 477, 526–528.
- Lee, G., Studer, L., 2010. Induced pluripotent stem cell technology for the study of human disease. *Nat. Methods* 7, 25–27.
- Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al., 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. *Lancet* 380, 2095–2128.

- Macleod, M.R., Fisher, M., O'Collins, V., Sena, E.S., Dirnagl, U., Bath, P.M., et al., 2009. Good laboratory practice: preventing introduction of bias at the bench. *Stroke* 40, e50–52.
- Macleod, M.R., Michie, S., Roberts, I., Dirnagl, U., Chalmers, I., Ioannidis, J.P., et al., 2014. Biomedical research: increasing value, reducing waste. *Lancet* 383, 101–104.
- Malkesman, O., Austin, D.R., Chen, G., Manji, H.K., 2009. Reverse translational strategies for developing animal models of bipolar disorder. *Dis. Model Mech.* 2, 238–245.
- McGonigle, P., Ruggeri, B., 2014. Animal models of human disease: challenges in enabling translation. *Biochem. Pharmacol.* 87, 162–171.
- McOmish, C.E., Burrows, E.L., Hannan, A.J., 2014. Identifying novel interventional strategies for psychiatric disorders: integrating genomics, 'environmentomics' and gene-environment interactions in valid preclinical models. *Br. J. Pharmacol.* 171, 4719–4728.
- Meisel, C., Meisel, A., 2011. Suppressing immunosuppression after stroke. *N. Engl. J. Med.* 365, 2134–2136.
- Meisel, C., Prass, K., Braun, J., Victorov, I., Wolf, T., Megow, D., et al., 2004. Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. *Stroke* 35, 2–6.
- Meisel, C., Schwab, J.M., Prass, K., Meisel, A., Dirnagl, U., 2005. Central nervous system injury-induced immune deficiency syndrome. *Nat. Rev. Neurosci.* 6, 775–786.
- Menalled, L., Brunner, D., 2014. Animal models of Huntington's disease for translation to the clinic: best practices. *Mov. Disord.* 29, 1375–1390.
- Menalled, L.B., Patry, M., Ragland, N., Lowden, P.A., Goodman, J., Minnich, J., et al., 2010. Comprehensive behavioral testing in the r6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. *PLoS One* 5, e9793.
- Mergenthaler, P., Dirnagl, U., Meisel, A., 2004. Pathophysiology of stroke: lessons from animal models. *Metab. Brain Dis.* 19, 151–167.
- Mergenthaler, P., Meisel, A., 2012. Do stroke models model stroke? *Dis. Model Mech.* 5, 718–725.
- O'Collins, V.E., Macleod, M.R., Donnan, G.A., Horky, L.L., van der Worp, B.H., Howells, D.W., 2006. 1,026 experimental treatments in acute stroke. *Ann. Neurol.* 59, 467–477.
- Perel, P., Roberts, I., Sena, E., Wheble, P., Briscoe, C., Sandercock, P., et al., 2007. Comparison of treatment effects between animal experiments and clinical trials: systematic review. *BMJ* 334, 197.
- Perrin, S., 2014. Preclinical research: make mouse studies work. *Nature* 507, 423–425.
- Philips, T., Rothstein, J.D., Pouladi, M.A., 2014. Preclinical models: needed in translation? A pro/con debate. *Mov. Disord.* 29, 1391–1396.
- Prabhakar, S., 2012. Translational research challenges: finding the right animal models. *J. Investig. Med.* 60, 1141–1146.
- Prass, K., Meisel, C., Hoflich, C., Braun, J., Halle, E., Wolf, T., et al., 2003. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. *J. Exp. Med.* 198, 725–736.
- Prinz, F., Schlange, T., Asadullah, K., 2011. Believe it or not: how much can we rely on published data on potential drug targets? *Nat. Rev. Drug Discov.* 10, 712.
- Ruggeri, B.A., Camp, F., Miknyoczki, S., 2014. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. *Biochem. Pharmacol.* 87, 150–161.
- Schwarz, S., Al-Shajlawi, F., Sick, C., Meairs, S., Hennerici, M.G., 2008. Effects of prophylactic antibiotic therapy with mezlocillin plus sulbactam on the incidence and height of fever after severe acute ischemic stroke: the Mannheim infection in stroke study (miss). *Stroke* 39, 1220–1227.
- Sena, E.S., van der Worp, H.B., Bath, P.M., Howells, D.W., Macleod, M.R., 2010. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. *PLoS Biol.* 8, e1000344.
- Shaltiel, G., Maeng, S., Malkesman, O., Pearson, B., Schloesser, R.J., Tragon, T., et al., 2008. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. *Mol. Psychiatry* 13, 858–872.
- Shultz, L.D., Brehm, M.A., Garcia-Martinez, J.V., Greiner, D.L., 2012. Humanized mice for immune system investigation: progress, promise and challenges. *Nat. Rev. Immunol.* 12, 786–798.
- Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., et al., 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 352, 987–996.
- Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., et al., 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. *N. Engl. J. Med.* 355, 1018–1028.
- Thomsen, G.M., Gowing, G., Svendsen, S., Svendsen, C.N., 2014. The past, present and future of stem cell clinical trials for ALS. *Exp. Neurol.* 262, 127–137.
- van de Beek, D., Wijdicks, E.F., Vermeij, F.H., de Haan, R.J., Prins, J.M., Spanjaard, L., et al., 2009. Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis. *Arch. Neurol.* 66, 1076–1081.
- van der Worp, H.B., Howells, D.W., Sena, E.S., Porritt, M.J., Rewell, S., O'Collins, V., et al., 2010. Can animal models of disease reliably inform human studies? *PLoS Med.* 7, e1000245.
- Westendorp, W.F., Nederkoorn, P.J., Vermeij, J.D., Dijkgraaf, M.G., van de Beek, D., 2011. Post-stroke infection: a systematic review and meta-analysis. *BMC Neurol.* 11, 110.
- Whiteside, G.T., Pomonis, J.D., Kennedy, J.D., 2013. An industry perspective on the role and utility of animal models of pain in drug discovery. *Neurosci. Lett.* 557 (Pt A), 65–72.
- Willner, P., 1986. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 10, 677–690.
- Xiong, Y., Mahmood, A., Chopp, M., 2013. Animal models of traumatic brain injury. *Nat. Rev. Neurosci.* 14, 128–142.